Longevity & AgingResearch PaperPaywall

Navitoclax plus ruxolitinib lifts spleen and symptom responses in myelofibrosis

Two trials suggest adding navitoclax to ruxolitinib improves spleen shrinkage and symptom relief in myelofibrosis patients who have already had a JAK inhibitor.

Thursday, November 12, 2026 0 views
Published in Leuk Lymphoma
Glowing 3D protein structure of BCL-xL bound by a small-molecule drug, set against stylized red and white blood cells

Summary

Myelofibrosis is a rare bone marrow cancer that causes an enlarged spleen, heavy symptoms, and marrow scarring. When JAK inhibitors such as ruxolitinib stop working or fall short, options are limited. This report presents two trials of navitoclax, an investigational drug that blocks cell-survival proteins in cancer cells. REFINE (phase 2) tested navitoclax alone or with ruxolitinib in patients previously treated with a JAK inhibitor. TRANSFORM-2 (phase 3) compared navitoclax plus ruxolitinib with best available therapy (BAT) in relapsed or refractory disease. The authors report higher rates of spleen volume reduction of at least 35% (SVR35) and symptom score improvement of at least 50% (TSS50) with the combination than with BAT, and than with navitoclax alone in an indirect comparison. Only the abstract was available, so exact figures and safety data are not covered here.

Detailed Summary

Myelofibrosis is a chronic blood cancer in which the bone marrow becomes scarred, the spleen enlarges, and patients suffer fatigue, night sweats, and other burdensome symptoms. JAK inhibitors like ruxolitinib are standard therapy, but many patients lose response or respond only partially. Treatments for this relapsed or refractory group remain limited.

This paper reports results from two studies of navitoclax, a drug that inhibits BCL-xL and BCL-2, proteins that help abnormal cells survive. REFINE was a phase 2 study of navitoclax alone or combined with ruxolitinib in patients previously treated with a JAK inhibitor. TRANSFORM-2 was a phase 3 study comparing navitoclax plus ruxolitinib against best available therapy (BAT) in patients with relapsed or refractory disease.

Per the abstract's plain language summary, the combination produced higher rates of SVR35 (a spleen volume reduction of at least 35%) and TSS50 (a total symptom score reduction of at least 50%) than BAT in TRANSFORM-2. In REFINE, the combination also appeared to outperform navitoclax monotherapy, though this was an indirect comparison. The authors conclude that the two drugs have complementary activity.

These findings support combining navitoclax with ruxolitinib for hard-to-treat myelofibrosis and suggest monotherapy may be less effective. Spleen and symptom endpoints matter to patients, but they are surrogate measures for the longer-term outcomes that count most.

Important caveats apply. Only the abstract was reviewed, so effect sizes, confidence intervals, safety, and tolerability data are unavailable to us. Navitoclax-class drugs are generally associated with lower platelet counts, which this abstract does not address. The monotherapy comparison was indirect, and several authors are employees of the sponsor, AbbVie. Readers should consult the full paper before drawing clinical conclusions.

Key Findings

  • TRANSFORM-2 (phase 3) found higher SVR35 rates with navitoclax plus ruxolitinib than with best available therapy.
  • TSS50 symptom-response rates were also higher with the combination than with best available therapy in TRANSFORM-2.
  • In REFINE (phase 2), the combination showed higher SVR35 and TSS50 rates than navitoclax alone, by indirect comparison.
  • Authors describe navitoclax and ruxolitinib as having complementary activity in relapsed or refractory myelofibrosis.
  • The population studied was patients previously treated with a JAK inhibitor, a difficult-to-treat group.

Methodology

The report combines the phase 2 REFINE study (navitoclax alone or with ruxolitinib) and the phase 3 TRANSFORM-2 study (navitoclax plus ruxolitinib versus best available therapy) in JAK inhibitor-treated myelofibrosis. Primary endpoints discussed are SVR35 and TSS50. The monotherapy-versus-combination comparison in REFINE is indirect.

Study Limitations

This summary relies only on the abstract and plain language summary, so quantitative results, safety, and durability of response are not assessed. The comparison with navitoclax monotherapy is indirect and cannot establish superiority. Spleen and symptom endpoints are surrogates, and the authors include sponsor employees.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: